Obtaining the Campaigns list from the server has failed!
Server response:
CM Ad cahger Server plugin is not active on https://legendarygroup.co/admanager/

Novavax starts COVID-19 vaccine trial for children aged six months to 11 years

U.S. biotech company Novavax, Inc., has started its phase 2b/3 Hummingbird global clinical trial. 

The trial will evaluate the safety, effectiveness (immunogenicity), and efficacy of two doses of the Novavax COVID-19 vaccine (NVX-CoV2373) in younger children aged six months through 11 years, followed by a booster at six months after the primary vaccination series.

“We are excited to begin the Hummingbird trial to study Nuvaxovid’s efficacy in children as young as six months through age 11,” said Stanley C. Erck, president and CEO of Novavax. 

“With a successful trial, we may have the opportunity to offer our COVID-19 vaccine to all age groups aged six months and older for protection against this ongoing pandemic.”

The trial will assess the Novavax COVID-19 vaccine in infants (six through 23 months of age), toddlers (two through five years) and children (six through 11 years).

The trial is an age de-escalation trial and age groups will be tested sequentially. Participants have begun dosing in the six to 11-year-old age group.

The post Novavax starts COVID-19 vaccine trial for children aged six months to 11 years appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Source

About the Author: Biotech Today

You might like

Obtaining the Campaigns list from the server has failed!
Server response:
CM Ad cahger Server plugin is not active on https://legendarygroup.co/admanager/